Secondary endpoints of phase II/III study confirm clear benefits from treatment with removab® for patients with malignant ascites
Fresenius today announced that further secondary endpoint data from a phase II/III study with removab® (catumaxomab) in…
Fresenius completes conversion into a European Company (SE)
Fresenius today announced that the conversion of Fresenius AG into a European Company (Societas Europaea) took effect on…
Fresenius Medical Care AG & Co. KGaA Announces the Offering of US$ 500 million of 10 Year Senior Notes for Refinancing Purposes
Fresenius Medical Care AG & Co. KGaA (“the Company”) (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS-p), the world…